Hemato in Medical Technology

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

...been providing comprehensive cancer care in the greater Triangle area for 30 years. Beginning as a single physician practice, originally named Raleigh hematology Oncology, CCNC has grown to a physician staff of thirteen medical oncologists, two radiation oncologists, a head and neck surgical oncologist and...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...ve results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of TELINTRA were published earlier in the Journal of hematology and Oncology, 13 May 2009; Vol. 2, No.20, pp. 20-32. The findings reported from these studies support the further development of TELINTRA. Phas...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

...th. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarc...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

...ational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation," presented at American Society of hematology annual meeting in December 2008. (2) Edoxaban tosylate is also known as DU-176b. (3) Schulman S., et al. Definition of major bl...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

...y by using these naturally occurring resectins with novel signaling activities to treat a wide variety of diseases, such as inflammation, automimmune, hematopoietic and metabolic disorders." The PNAS publication can be accessed at: http://www.pnas.org/content/early/2009/06/25/0905339106.abstract ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...cal study which demonstrate a real benefit to the use of thiarabine in RA." "Our current development focus for thiarabine is for the treatment of hematological cancers," stated Jeffrey B. Davis, President & CEO. "But, we believe these new RA data provide compelling evidence that Thiarabine should ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...openia, have been infrequently reported with SIMPONI in clinical trials. Discontinuation of SIMPONI should be considered in patients with significant hematologic abnormalities. The concurrent administration of TNF-antagonists with anakinra or abatacept is not recommended. Concurrent administration...

UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients

...ternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymph...id Mounzer Agha, M.D., clinical director of UPCI's hematopoietic Stem Cell Transplant Program. "Using umbil...litating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida ...

Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options

...ms. The ASCO summaries are "quick read" reviews of key oral sessions and poster presentations, which are handpicked by leading experts in oncology and hematology for the Clinical Care Options website. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company commit...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...s a common disorder among immunocompromised cancer patients after receiving hematopoietic cell transplantation. Unlike organ transplants where the patient's ...tment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 c...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

...d safety margin. In our prior 21-day Phase 1 clinical trial, which examined hematological parameters as key markers of oxazolidinone safety, the 200 mg dose ...se events. Laboratory results showed no significant shifts from baseline in hematology or chemistry parameters, including platelets or liver enzymes. "...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...resented Data at the 14th Congress of the European hematology Association Showing High Response Rate in Pat...momab (MT103) at the 14th Congress of the European hematology Association (EHA) in Berlin, Germany, showing...ed in this phase 2 clinical trial were in complete hematological remission following intense chemotherapy r...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... Data Presented at Meeting of European hematology Association Confirms High Response Rate and D...ymphoma (NHL) at the 14th Congress of the European hematology Association (EHA), held June 4 to 7 in Berlin...ata presented at the 14th Congress of the European hematology Association. The webcast will be available o...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...el trial of 145 lymphoma patients was presented at the 14th annual European hematology Association congress in Berlin, Germany. Results show that 33% of pati...common side effect with Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with A...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

... Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK. The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA ...

Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries

...ion for even the most critical patient. This is minimally invasive, efficient, safe and effective. The concentrations of endothelial progenitor cells, hematopoietic stem cells, and mesenchymal stem cells have adhesion properties that ensure the cells remain localized where we need them to promote tissue gr...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Data from the Phase 2 clinical ...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstro...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...y Expanded Clinical Program Now Includes Solid and hematological Malignancies ROCKVILLE, Md., June 1 /...extend the possible indications for ENMD-2076 into hematological malignancies where preclinical data have b... including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

...es. Additionally, two patients on the gemcitabine arm died due to causes possibly attributed to treatment-related toxicities. Most side effects were hematologic, including anemia (low red blood cell count), neutropenia (low white blood cell count) and thrombocytopenia (low blood platelet count). "...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. "In th...rfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib i...filzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including mul...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...study of patients with advanced refractory colorectal carcinoma (CRC). The data were presented by lead investigator Dirk Strumberg, MD, Department of hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Germany. Data from the Phase I dose-finding study in CRC sh...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... increasing local control in patients with advanced unresectable head and neck cancer," said Fadlo Khuri, MD, Professor and Roberto Goizueta Chair of hematology and Medical Oncology at Emory University , Atlanta, GA, USA. Dr. Khuri, a renowned head and neck cancer expert, also added: "These data may he...

Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

...said Zeina Nahleh, M.D., co-director of the Breast Oncology Multidisciplinary Team at Karmanos Cancer Institute and assistant professor of medicine in hematology and oncology at Wayne State University School of Medicine. "We wanted to see how much expression of the protein was present. We were surprised ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...and GSK." The advisory committee made its decision based on an interim analysis of a pivotal trial that was presented at the American Society of hematology 2008 annual meeting and will be presented at the American Society of Clinical Oncology 2009 annual meeting. About CLL CLL is the most co...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

...n the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preven...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...ropathy-sparing alternative to FOLFOX (p<0.0019). With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and s...than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) an...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...dverse events affected the gastrointestinal tract, hematopoietic system and other general symptoms such as ...finitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to th...xicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was ...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

...tor Administered in Dual Cord Blood Transplant for hematologic Malignancy LA JOLLA, Calif., May 27 /PR...ule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function throug...lical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma,...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

...y 29 - June 2, 2009 in Orlando, Florida. PAREXEL's hematology and oncology experts will be available during...al Research Services, PAREXEL. "Our global team of hematology and oncology experts helps clients advance im...th factors, antiemetics, and analgesics. PAREXEL's hematology/Oncology Therapeutic Area Team offers experti...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

...ine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer Presenter: Steven Anthony, DO, Evergreen hematology and Oncology Date and Time: Saturday, May 30, 2009, 8:00 AM - 12:00 PM Session Title: Developmental Therapeutics Session Type: Poster...

Mutant Genes in High-Risk Childhood Leukemias Identified

... and more than 120 research scientists, supported by more than $50 million in grants annually. The UNM Cancer Center has major programs in research in hematologic malignancies, focusing specifically on leukemia. As the Official Cancer Center of the State of New Mexico, the Center served 7,600 new patients ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

...ment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers. The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cel...

TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin

...e-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European hematology Association (EHA) conference on June 6, 2009 in Berlin. www.targegen.com About TargeGen, Inc . TargeGen, Inc. is a privately h...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities. A n increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination ...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

...exercised when administering AZOR to patients with severe hepatic impairment. Laboratory Tests There was a greater decrease in hemoglobin and hematocrit in the combination product compared to either component alone. Adverse Reactions The only adverse reaction that occurred in greater than...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

...relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinu...

BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available

...pliers that the majority of respondents differentiate their stem cells into hematopoeitic and epithelial cells, other cell types are expected to be of increa... and dendritic cells are projected to be differentiated states as common as hematopoeitic and epithelial cells. These findings have implications for product ...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

...e relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinu...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... the United States, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preve...